PROCEPT BioRobotics (PRCT): 7-month performance

 

PROCEPT BioRobotics (PRCT) began trading on the Nasdaq on Wed 15 Sep 21

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). 

• Sector(s): Healthcare
• Industry: Medical Devices
• Full Time Employees: 234
• Incorporated in 2007 
• Headquartered in Redwood City, California
• https://www.procept-biorobotics.com

Procept, Inc. priced upsized 6.556 mln share IPO at $25.00 per share, above the $22-24 expected range

IPOs this week : Sept 13 - 17, 21 (wk 37)

IPOs expected to price

• Sportradar Group (SRAD), 
• Dutch Bros (BROS), 
• Definitive Healthcare Corp. (DH), 
• Thoughtworks Holding (TWKS), 
• On Holding (ONON), 
• PROCEPT BioRobotics Corp. (PRCT) and 
• ForgeRock (FORG) 

Software consultancy firm Thoughtworks Holding could trade with the highest market cap of the group, with the Siemens-backed company aiming for a valuation of over $6B. in U.S. 

IPO lockup expirations

• Olo (NYSE:OLO), 
• Jowell Global (NASDAQ:JWEL), 
• Alzamend Neuro (NASDAQ:ALZN), 
• Sun Country Airlines (NASDAQ:SNCY), 
• Tuya (NYSE:TUYA), 
• Vine Energy (NYSE:VEI), 
• Duckhorn Portfolio (NYSE:NAPA), 
• Molecular Partners (NASDAQ:MOLN), 
• Gain Therapeutics (NASDAQ:GANX), 
• Instil Bio (NASDAQ:TIL), 
• Connect Biopharma (NASDAQ:CNTB), 
• Finch Therapeutics Group (NASDAQ:FNCH) and 
• AFC Gamma (NASDAQ:AFCG).